Two FDA pathways govern compounded peptide drugs: section 503A for traditional prescription compounding and section 503B for registered outsourcing facilities. Both limit which bulk substances may be used, and the FDA's provisional category assignments show where enforcement stands. A statutory…
Peptide compounding sits on two statutory tracks, and the boundary between them is a number. A peptide of 40 residues or fewer is a drug for regulatory purposes, and it can in principle be compounded under section 503A or section 503B of the Federal Food, Drug, and Cosmetic Act. A peptide longer than 40 amino acids meets the statutory definition of a protein, is regulated as a biologic, and is outside both compounding sections entirely. Inside the drug track, the decisive question is which bulk drug substance the peptide was made from. The FDA assigns substances that do not yet qualify through the main routes to three provisional categories, and the category, not the chemistry alone, tells a compounder how much enforcement risk a product carries. Researchers and buyers who read category status as a safety verdict, or take a research-use-only label as a license for clinical use, will misread the system.
The modern framework dates to the Drug Quality and Security Act of 2013, which added sections 503A and 503B to the FD&C Act. Congress wrote the law in direct response to the 2012 fungal meningitis outbreak traced to a compounding pharmacy. The act created two distinct regulatory pathways, each with its own obligations and limits.
Section 503A governs traditional pharmacy compounding. A pharmacist or physician compounds a drug for an identified individual patient on the basis of a prescription. The product is not an FDA-approved drug; the section instead sets the conditions under which compounding such a product for a named patient is lawful. Those conditions are narrow. The drug must be made for a specific patient, and the bulk drug substance used must be one the statute allows.
Section 503B governs FDA-registered outsourcing facilities. An outsourcing facility may compound drugs without patient-specific prescriptions, producing batches in advance for hospitals and clinics to stock. In exchange for that flexibility, the facility must register with the FDA and comply with current good manufacturing practice requirements. The two pathways embody different bargains: 503A keeps compounding small and patient-specific, while 503B permits production-scale compounding under manufacturing discipline.
Both sections share one restriction: only certain bulk drug substances may go into the products.
| Pathway | Who compounds | Prescription needed | Manufacturing standard | Bulk substance limit |
|---|---|---|---|---|
| 503A | Pharmacy or physician | Yes, for an identified patient | Pharmacy practice under the section's conditions | Qualifying bulk substances only |
| 503B | FDA-registered outsourcing facility | No, may compound in advance | Current good manufacturing practice | Qualifying bulk substances only |
The shared restriction carries most of the regulatory weight for peptides. The FDA's review begins with the source substance, not the finished formulation. A pharmacy that buys a catalog peptide, suspends it in a vehicle, and dispenses it as an injection has already committed to a bulk substance whose regulatory status is either resolved, pending, or adverse. The compounding itself does not change that status.
A bulk drug substance qualifies for compounding through one of three routes. It may appear in a United States Pharmacopeia or National Formulary monograph. It may be a component of an FDA-approved drug. Or it may appear on a list the FDA develops through regulation. The first two routes are stable and comparatively easy to check. The third is the one still being built, and it is where most peptide questions live.
For substances that do not qualify through a monograph or an approved drug component, the FDA maintains provisional category assignments while nominations are being evaluated. There are three categories.
| Category | Meaning | Enforcement position |
|---|---|---|
| 1 | Nominated with sufficient supporting information; no significant safety concerns identified so far | FDA has said it does not intend to take enforcement action while review continues |
| 2 | FDA has identified significant safety risks | No enforcement discretion; not a formal finding of unsafety |
| 3 | Nomination lacks sufficient supporting information to permit evaluation | No enforcement discretion |
The category assignments are administrative positions during rulemaking, not approvals, and they can change as nominations are evaluated. That provisional character is easy to lose sight of, because the categories read like verdicts. They are better understood as the FDA's current enforcement posture: a statement of where the agency will and will not extend discretion, not a final judgment on the science.
Several peptides commonly sold for research have been placed in Category 2. The FDA's stated reasons vary by substance and include immunogenicity concerns, the absence of characterization data, peptide-related impurity profiles, and insufficient information to assess safety at the proposed doses. A Category 2 placement does not assert that a compound is unsafe as a finding of fact; it records that the FDA identified risks significant enough to preclude enforcement discretion. The FDA has issued communications addressing both compounders and sellers marketing unapproved products, and a Category 2 substance is squarely within that enforcement attention.
The reasons the FDA cites for Category 2 placements are worth parsing, because they track what is genuinely difficult about peptide products. Peptides are assembled stepwise from amino acids, and the finished material carries the trace chemistry of that process: deletion sequences, truncated chains, oxidized residues, and aggregates. For longer peptides, such impurities can be immunogenic, and immunogenicity cannot be assessed from a certificate of analysis that lists only purity. The absence of characterization data matters because batch-to-batch consistency, not peak purity alone, is what determines whether a product can be used safely at a proposed dose. A category assignment is a regulatory judgment made against that background, and it says nothing about the quality of any individual lot.
The single most important number in this area is 40. The Biologics Price Competition and Innovation Act amended the FD&C Act to define a protein as any alpha amino acid polymer with a specific defined sequence greater than 40 amino acids in size. A product that meets that definition is regulated as a biologic. Because sections 503A and 503B apply to drugs, a peptide above the threshold cannot be compounded under either pathway. The compounding question never opens.
Peptides of 40 residues or fewer remain drugs for regulatory purposes and may fall within drug compounding rules, provided the bulk substance and the rest of the section's conditions are met. Note the exact reading of the size language: the definition catches polymers greater than 40 amino acids, so a peptide of exactly 40 residues is still a drug.
The 40-residue boundary is a definitional line about regulatory pathway, not a statement about pharmacology or safety. A 41-residue peptide is not inherently more dangerous than a 39-residue one. The statute simply assigns each side to a different regulatory regime with different manufacturing expectations. For a buyer or compounder, the check is mechanical: count the residues in the sequence. Above 40, the product is a biologic and the 503A or 503B analysis stops. At or below 40, the bulk substance routes and categories take over.
A product labeled for research use only sits outside the clinical pathways by definition. It is not an approved drug. It is not a compounded preparation dispensed under a prescription for an identified patient. And it carries no FDA finding of safety or efficacy for human use. The label describes an intended use outside clinical treatment. It does not create a lawful route to human administration, and it cannot be converted into one by a prescriber's signature.
This is the point most often misunderstood in the market for research peptides. A vial labeled for research use only that is compounded into a product for a patient is not an off-label use of an approved drug; it is an unapproved product with no lawful pathway at all. The FDA's enforcement history in this area runs through warning letters, import alerts, and injunctions aimed at both compounders and sellers. A research-use label has not shielded a product from those measures, and the agency has addressed the practice of marketing unapproved products while labeling them for research.
The governing documents for any decision are the FDA's own bulk drug substance lists and the Federal Register notices that accompany them. Secondary summaries, including this one, age quickly: category placements are revised as nominations are evaluated, and an interim policy can be withdrawn as the review proceeds. Treat any published list as a snapshot, check the current Federal Register docket, and record the date of the check.
A practical sequence for evaluating a peptide looks like this:
The same logic applies at the level of a research lab's purchasing. Buying a research-use peptide for in vitro or animal work is routine and lawful, because the product goes to a non-clinical use. The problems arise when a material moves from that channel into a clinical formulation. At that point the residue count, the bulk substance category, and the compounding pathway all become relevant, and none of them can be fixed by relabeling.
The interim category system is explicitly interim, and the rulemaking that would replace it has not produced a final structure. Several questions remain open. The FDA has not published the full evidentiary record behind individual Category 2 placements, so independent assessment of which peptides belong there and why is difficult. The kinds of supporting information required for a move into Category 1 have not been specified as a checklist; nominators learn the standard through the evaluation process. And the specific evidence that would move a substance from Category 2 or Category 3 into Category 1 has not been defined in advance.
The unresolved center is dose. Several Category 2 placements rest on insufficient information to assess safety at the proposed doses, which points to the shape of a sufficient submission: characterization data for the substance, an impurity profile that accounts for the way peptides are made, and exposure information tied to the doses actually used. Whether the FDA will accept such data for substances that currently lack it, and how the final rules will treat substances now in each category, remains to be seen.
Until the rulemaking concludes, category assignments are the working currency of peptide compounding regulation. They are not approvals. They are administrative positions that change as nominations are evaluated, and they should be read as statements about enforcement, not as verdicts on the biology. A buyer who keeps that distinction in view, checks the current lists, and treats research-use labels as research-use labels will be reading the system correctly.
Vendors referenced: Embody.
Related reading: Trofinetide for Rett Syndrome: Mechanism and Clinical Evidence, FDA-Approved Trofinetide: A New Treatment for Rett Syndrome, Trofinetide for Rett Syndrome: Mechanisms and FDA Approval Evidence.